NCT00451763View on ClinicalTrials.gov

Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia

PHASE3CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2007

Conditions
RetinaTelangiectasis
Interventions
DRUG

Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)

Trial Locations (1)

41253-190

From the Retina and Vitreous Service, Department of Ophthalmology. Sao Rafael Hospital, Monte Tabor Foudation, Salvador

All Listed Sponsors
collaborator

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

OTHER_GOV

lead

University of Sao Paulo

OTHER

NCT00451763 - Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia | Biotech Hunter | Biotech Hunter